Login / Signup

Cannabinoid treatment for autism: a proof-of-concept randomized trial.

Adi AranMoria HarelHanoch CassutoLola PolyanskyAviad SchnappNadia WattadDorit ShmueliDaphna GolanF Xavier Castellanos
Published in: Molecular autism (2021)
This interventional study provides evidence that BOL-DP-O-01-W and BOL-DP-O-01, administrated for 3 months, are well tolerated. Evidence for efficacy of these interventions are mixed and insufficient. Further testing of cannabinoids in ASD is recommended. Trial registration ClinicalTrials.gov: NCT02956226. Registered 06 November 2016, https://clinicaltrials.gov/ct2/show/NCT02956226.
Keyphrases